Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline

被引:8
作者
Maruzzo, Marco [1 ]
Brunello, Antonella [1 ]
Diminutto, Alberto [1 ]
Rastrelli, Marco [2 ]
Basso, Umberto [1 ]
机构
[1] IRCCS, IOV, Dept Clin & Expt Oncol, Med Oncol Unit 1, Via Gattamelata 64, I-35128 Padua, Italy
[2] IRCCS, IOV, Oncol Surg Unit, Via Gattamelata 64, I-35128 Padua, Italy
关键词
first-line chemotherapy; leiomyosarcoma; response; trabectedin; SOFT-TISSUE SARCOMA; RETROSPECTIVE POOLED ANALYSIS; RANDOMIZED PHASE-II; LIPOSOMAL DOXORUBICIN; EUROPEAN ORGANIZATION; MYXOID LIPOSARCOMAS; SINGLE-INSTITUTION; CANCER; ECTEINASCIDIN-743; CHEMOTHERAPY;
D O I
10.1097/CAD.0000000000000326
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic chemotherapy comprising anthracycline monotherapy is the standard regimen for metastatic soft tissue sarcomas, particularly leiomyosarcomas, which have limited sensitivity to ifosfamide. However, the optimal chemotherapy regimen for elderly patients, especially those considered unfit for anthracyclines, is undefined. Trabectedin is a potent marine-derived antineoplastic drug with documented activity in liposarcomas and leiomyosarcomas. It is registered in Europe for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. We report the long-term response to first-line trabectedin therapy in an elderly patient with metastatic leiomyosarcoma unfit for standard therapy. A 66-year-old woman underwent resection of a pelvic epithelioid leiomyosarcoma with positive margins in December 2002, followed by postoperative radiotherapy. In February 2012, she was diagnosed with multiple lung lesions and local relapse in the pelvis. As she was considered unsuitable for both anthracycline and ifosfamide because of cardiovascular comorbidities and because she was highly anxious at the prospect of developing alopecia, vomiting, and fatigue, we commenced treatment with trabectedin at 75% of the standard dose of 1.5mg/m(2) every 3 weeks. Treatment was well tolerated, and the patient continued treatment for 25 cycles, with disease stabilization according to the RECIST criteria and a partial response according to the Choi criteria. Disease progression was observed in November 2013 and the patient died 20 months after the diagnosis of metastases. Trabectedin may represent an alternative option for highly selected elderly patients with metastatic sarcoma and unfit for anthracyclines; careful monitoring of toxicities is strongly recommended.
引用
收藏
页码:264 / 267
页数:4
相关论文
共 31 条
  • [1] [Anonymous], SARCOMA
  • [2] [Anonymous], YOND TRAB SUMM PROD
  • [3] Multidimensional geriatric evaluation in elderly cancer patients: a practical approach
    Basso, U
    Monfardini, S
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2004, 13 (05) : 424 - 433
  • [4] Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70 years)
    Basso, Umberto
    Roma, Anna
    Brunello, Antonella
    Falci, Cristina
    Fiduccia, Pasquale
    Banzato, Alberto
    Bononi, Antonio
    Gusella, Milena
    Vamvakas, Lampros
    Zagonel, Vittorina
    Monfardini, Silvio
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (04) : 340 - 345
  • [5] Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
    Blay, Jean-Yves
    Leahy, Michael G.
    Binh Bui Nguyen
    Patel, Shreyaskumar R.
    Hohenberger, Peter
    Santoro, Armando
    Staddon, Arthur P.
    Penel, Nicolas
    Piperno-Neumann, Sophie
    Hendifar, Andrew
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Chawla, Sant P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (06) : 1137 - 1147
  • [6] A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
    Bui-Nguyen, B.
    Butrynski, J. E.
    Penel, N.
    Blay, J. Y.
    Isambert, N.
    Milhem, M.
    Kerst, J. M.
    Reyners, A. K. L.
    Litiere, S.
    Marreaud, S.
    Collin, F.
    van der Graaf, W. T. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) : 1312 - 1320
  • [7] Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
    Cesne, A. L.
    Judson, I.
    Maki, R.
    Grosso, F.
    Schuetze, S.
    Mehren, M. V.
    Chawla, S. P.
    Demetri, G. D.
    Nieto, A.
    Tanovic, A.
    Blay, J-Y
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (07) : 1717 - 1724
  • [8] Response evaluation of gastrointestinal stromal tumors
    Choi, Haesun
    [J]. ONCOLOGIST, 2008, 13 : 4 - 7
  • [9] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    Choi, Haesun
    Charnsangavej, Chuslip
    Faria, Silvana C.
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Benjamin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1753 - 1759
  • [10] Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
    Demetri, George D.
    von Mehren, Margaret
    Jones, Robin L.
    Hensley, Martee L.
    Schuetze, Scott M.
    Staddon, Arthur
    Milhem, Mohammed
    Elias, Anthony
    Ganjoo, Kristen
    Tawbi, Hussein
    Van Tine, Brian A.
    Spira, Alexander
    Dean, Andrew
    Khokhar, Nushmia Z.
    Park, Youn Choi
    Knoblauch, Roland E.
    Parekh, Trilok V.
    Maki, Robert G.
    Patel, Shreyaskumar R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : 786 - +